"Ceftazidime" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients.
| Descriptor ID |
D002442
|
| MeSH Number(s) |
D02.065.589.099.249.210.150 D02.886.665.074.210.150 D03.633.100.300.249.210.150
|
| Concept/Terms |
Ceftazidime- Ceftazidime
- Ceftazidime Pentahydrate
- Pentahydrate, Ceftazidime
|
Below are MeSH descriptors whose meaning is more general than "Ceftazidime".
Below are MeSH descriptors whose meaning is more specific than "Ceftazidime".
This graph shows the total number of publications written about "Ceftazidime" by people in this website by year, and whether "Ceftazidime" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 3 | 5 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 2 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 3 | 0 | 3 |
| 2023 | 3 | 0 | 3 |
| 2024 | 3 | 1 | 4 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ceftazidime" by people in Profiles.
-
Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii. Diagn Microbiol Infect Dis. 2025 Nov; 113(3):116991.
-
Bacteriophage treatment is effective against carbapenem-resistant Klebsiella pneumoniae (KPC) in a neutropenic murine model of gastrointestinal translocation and renal infection. Antimicrob Agents Chemother. 2025 02 13; 69(2):e0091924.
-
Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study. Lancet Infect Dis. 2025 May; 25(5):574-584.
-
In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2024 Sep; 38:252-255.
-
The mechanism of ceftazidime and cefiderocol hydrolysis by D179Y variants of KPC carbapenemases is similar and involves the formation of a long-lived covalent intermediate. Antimicrob Agents Chemother. 2024 03 06; 68(3):e0110823.
-
Structural insights into the molecular mechanism of high-level ceftazidime-avibactam resistance conferred by CMY-185. mBio. 2024 Feb 14; 15(2):e0287423.
-
Klebsiella pneumoniae carbapenemase variant 44 acquires ceftazidime-avibactam resistance by altering the conformation of active-site loops. J Biol Chem. 2024 01; 300(1):105493.
-
High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated ?-lactamase CMY-185 variant. J Antimicrob Chemother. 2023 10 03; 78(10):2442-2450.
-
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE)?bloodstream infections. Int J Antimicrob Agents. 2023 Apr; 61(4):106760.
-
Mapping the determinants of catalysis and substrate specificity of the antibiotic resistance enzyme CTX-M ?-lactamase. Commun Biol. 2023 01 12; 6(1):35.